Alacrita was engaged due diligence and valuation support by a listed clinical stage biotechnology company. The biotech needed to benchmark the technical strengths and weaknesses of two pipeline products relative to competition and to establish a valuation trajectory for both products at typical value-inflection points. We were also asked to consider how continued internal development may affect shareholder value compared to out-licensing, co-development or spin-out of each product. 


Alacrita conducted a high level due diligence of the two projects covering:

  • Scientific rationale and preclinical proof-of-concept dataset;
  • Preclinical development package;
  • Manufacturing/CMC approach for clinical trials and beyond;
  • Competitive position vs current and pipeline products;
  • Key risks (safety/tox, clinical, regulatory, manufacturing, market, etc.).

We then benchmarked the two products against competitive technologies, exploring:

  • Existing treatment pathways and related medical and clinical practice;
  • The strength of pre-clinical/clinical data on key identified competitor programs;
  • The client's proprietary IP (filed and unfiled) to identify its distinctive value in comparison with competing technologies;
  • The underlying assumptions within the products’ draft target product profiles (TPPs);
  • The potential positioning of both programs relative to forecast competition at launch.

This fed through into a Monte Carlo rNPV analysis where we assessed the value at key milestones (e.g. initiation of pivotal trials, submission for approval, etc). Finally, we benchmarked the valuations against partnering and M&A comparables enabling us to develop recommendations for maximizing shareholder value.

Alacrita's due diligence services

Since our inception over a decade ago, we've conducted more than 200 major due diligence assignments, covering a wide range of life science companies, programs and therapeutics. There are few firms that can match the level of our expertise, which is bolstered by our ability to draw in expert consultants with specialized knowledge in the core area of each project we work on. 

Click here to learn more


Contact Us
For more for information on our due diligence and valuation services, please contact us.

Additional Due Diligence Case Studies

Due diligence of first-in-class monoclonal antibody candidate drug

Challenge: A biopharma company required expert due diligence for a potential transaction with a clinical stage biotech focusing in inflammation and fibrosis. Alacrita was commissioned to...

Pre-due diligence of two early-stage assets: a nano-ADC & a small molecule

Challenge: A pharma company sought Alacrita's support in providing high-level go/no-go pre-due diligence of two early-stage strategic investment opportunities. The company had so far been...

Technical and commercial due diligence of two pipeline products

Challenge: Alacrita was engaged due diligence and valuation support by a listed clinical stage biotechnology company. The biotech needed to benchmark the technical strengths and weaknesses...

Due diligence on reinvestment in VC-backed biotech

Challenge: A family office invested in a European, VC-backed company sought Alacrita's expert view of re-investing in the company, following a Phase III trial failure in the immunology...

Expert witness to support pharma litigation process

Challenge: A major global law firm required an expert witness to support a litigation process between it client and another Big Pharma company.

DD for a biotech developing an AI-driven drug discovery platform

Challenge: A biotech company had developed an AI-driven drug discovery platform to discover phytocompounds and bioactives with the potential to impact human health. Alacrita was retained to...